Rovadicitinib for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Nov 2024: Trial registered, NCT06682169
  2. 20 Nov 2024: Trial started, NCT06682169

The trials

NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

State
Under way
Phase
Phase 3
People
182 planned
Started
20 Nov 2024
Primary completion
Oct 2029
Arms
Rovadicitinib
Results
None posted
  1. 12 Nov 2024: Trial registered
  2. 20 Nov 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.